Body Composition
Body composition analysis offers insights into the quality of weight loss and patient health. These powerful tools support decision-making in drug development across a broad spectrum of clinical trials (i.e. obesity, neuromuscular disorders, cancer cachexia).
Read More
Cardiometabolic
Multi-organ services delivered through quantitative MRI and DXA to support obesity, metabolic, and neuromuscular disease-focused clinical trials.
Read More
MASLD/MASH & Cirrhosis
Accurate and precise non-invasive imaging biomarkers for characterizing and monitoring treatment response.
Read More
Autoimmune Disease
Accurate and precise non-invasive imaging biomarkers for characterizing and monitoring treatment response.
Read More
Gastrointestinal Disease
Rapid, high-quality sample processing with a fully digitized reporting workflow and quantitative AI-pathology.
Read More
Oncology Solutions
Integrated analysis of our noninvasive, multi-organ & tumor characterization software, digital pathology, and endoscopy, enables a deeper rapid analysis of the patient and their cancer.
Read More
Our Experience and Network
1200+
Locations Worldwide
100+
Research Partners
90+
Papers Published
75+
Interventional Trials
40,000+
Trial Datasets Processed
Case Studies
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
R. Loomba, M.L. Hartman, E.J. Lawitz, R. Vuppalanchi, J. Boursier, E. Bugianesi, M. Yoneda, C. Behling, O.W. Cummings, Y. Tang, B. Brouwers, D.A. Robins, A. Nikooie, M.C. Bunck, A. Haupt, and A.J. Sanyal, for the SYNERGY-NASH Investigators*
The New England Journal of Medicine
Read ArticleRandomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
R. Loomba, Arun J. Sanyal, Kris V. Kowdley, Deepak L. Bhatt, Naim Alkhouri, Juan P. Frias, Pierre Bedossa, Stephen A. Harrison, Donald Lazas, Robert Barish, Mildred D. Gottwald, Shibao Feng, Germaine D. Agollah, Cynthia L. Hartsfield, Hank Mansbach, Maya Margalit, and Manal F. Abdelmalek
The New England Journal of Medicine
Read ArticleEffect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
Stephen A. Harrison, Sarah K. Browne,John J. Suschak,Shaheen Tomah, Julio A. Gutierrez, Jay Yang, M. Scot Roberts, M. Scott Harris
Journal of Hepatology
Read ArticleAWS Health Innovation Podcast
In this episode of the AWS Health Innovation Podcast, Amrita Sarkar, Principal Healthcare and Life Sciences Startups Business Development Manager at Amazon Web Services, sits down with Rajarshi Banerjee, aka ‘Banjo’, the CEO of, a company revolutionizing the way we diagnose and monitor chronic diseases.